Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial.

Stromberg D, Raymond T, Samuel D, Crockford D, Stigall W, Leonard S, Mendeloff E, Gormley A.

Ann N Y Acad Sci. 2012 Oct;1270:59-65. doi: 10.1111/j.1749-6632.2012.06710.x.

PMID:
23050818
2.
3.

Therapeutic potential of thymosin β4 in myocardial infarct and heart failure.

Stark C, Taimen P, Tarkia M, Pärkkä J, Saraste A, Alastalo TP, Savunen T, Koskenvuo J.

Ann N Y Acad Sci. 2012 Oct;1269:117-24. doi: 10.1111/j.1749-6632.2012.06695.x.

PMID:
23045979
4.

[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].

Goey AK, Schellens JH, Beijnen JH, Huitema AD.

Ned Tijdschr Geneeskd. 2010;154:A1155. Review. Dutch.

PMID:
20619024
5.

Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice.

Polanski AK, Ebner A, Ebner B, Hofmann A, Steinbronn N, Brandt A, Forkmann M, Tausche AK, Morawietz H, Strasser RH, Wunderlich C.

J Cardiovasc Pharmacol. 2013 Jun;61(6):545-52. doi: 10.1097/FJC.0b013e31828de47c.

PMID:
23474841
6.

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Cvetković RS, Scott LJ.

Drugs. 2005;65(7):1005-24. Review.

PMID:
15892593
7.

Thymosin β4 and cardiac protection: implication in inflammation and fibrosis.

Gupta S, Kumar S, Sopko N, Qin Y, Wei C, Kim IK.

Ann N Y Acad Sci. 2012 Oct;1269:84-91. doi: 10.1111/j.1749-6632.2012.06752.x. Review.

PMID:
23045975
8.

Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection.

Hinkel R, El-Aouni C, Olson T, Horstkotte J, Mayer S, Müller S, Willhauck M, Spitzweg C, Gildehaus FJ, Münzing W, Hannappel E, Bock-Marquette I, DiMaio JM, Hatzopoulos AK, Boekstegers P, Kupatt C.

Circulation. 2008 Apr 29;117(17):2232-40. doi: 10.1161/CIRCULATIONAHA.107.758904. Epub 2008 Apr 21.

9.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD.

Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16.

10.

Cardioprotective interventions for cancer patients receiving anthracyclines.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD003917. doi: 10.1002/14651858.CD003917.pub4. Review.

PMID:
21678342
11.

Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.

Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, Jacobs ML, Wernovsky G, Mahle WT, Murphy JD, Nicolson SC, Steven JM, Spray TL.

Pediatrics. 2001 Jul;108(1):61-70.

PMID:
11433055
12.

Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart.

Bollini S, Riley PR, Smart N.

Expert Opin Biol Ther. 2015;15 Suppl 1:S163-74. doi: 10.1517/14712598.2015.1022526. Epub 2015 Jun 22. Review.

PMID:
26094634
13.

Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.

Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA.

Br J Pharmacol. 2007 Jul;151(6):771-8. Epub 2007 May 21.

14.

Protection of thymosin beta-4 on corneal endothelial cells from UVB-induced apoptosis.

Ho JH, Su Y, Chen KH, Lee OK.

Chin J Physiol. 2010 Jun 30;53(3):190-5.

PMID:
21793328
15.

Controlled delivery of thymosin β4 for tissue engineering and cardiac regenerative medicine.

Chiu LL, Reis LA, Radisic M.

Ann N Y Acad Sci. 2012 Oct;1269:16-25. doi: 10.1111/j.1749-6632.2012.06718.x. Review.

PMID:
23045966
16.

Development of thymosin beta4 for treatment of patients with ischemic heart disease.

Crockford D.

Ann N Y Acad Sci. 2007 Sep;1112:385-95.

PMID:
17947592
17.

N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: results of a randomized, double-blind, placebo-controlled clinical trial.

Tossios P, Bloch W, Huebner A, Raji MR, Dodos F, Klass O, Suedkamp M, Kasper SM, Hellmich M, Mehlhorn U.

J Thorac Cardiovasc Surg. 2003 Nov;126(5):1513-20.

18.

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE.

N Engl J Med. 2004 Jul 8;351(2):145-53.

19.

Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia.

Thatcher JE, Welch T, Eberhart RC, Schelly ZA, DiMaio JM.

Ann N Y Acad Sci. 2012 Oct;1270:112-9. doi: 10.1111/j.1749-6632.2012.06681.x. Review.

PMID:
23050826
20.

Supplemental Content

Support Center